GRAY - Graybug Vision reaches a three-month high on nearly ten times average volume

Marcelo Ricardo Daros/iStock via Getty Images Adding more than a quarter of its value today so far, clinical-stage biopharmaceutical company Graybug Vision ([[GRAY]] +26.5%) is on course to record its biggest one-day gain since December. ~19.2M Graybug shares have changed hands today, indicating ~9.9x the average volume. If the rally holds, the micro-cap stock with over a quarter of its float on loan is on track to approach its highest level since March. The company shares have well underperformed the broader market so far this year, as indicated in the graph. In May, Graybug reported the results from full-data analysis of the Phase 2b ALTISSIMO trial of its lead asset GB-102 in Wet- age-related macular degeneration ((AMD)). Given the promising initial Phase 2b trial results for GB-102 in Wet AMD, the patient, long-term hold investors should consider Graybug, Seeking Alpha contributor Donovan Jones noted in a bullish thesis on the company before its

For further details see:

Graybug Vision reaches a three-month high on nearly ten times average volume